Status:
COMPLETED
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combi...
Eligibility Criteria
Inclusion
- Advanced or metastatic pretreated NSCLC
- Measurable disease
- Adequate hematologic, hepatic and renal functions.
- ECOG Performance Status 0-2
Exclusion
- Inability to swallow capsules
- Recent significant cardiovascular disease
- Women who are pregnant or breastfeeding
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00103831
Last Update
March 2 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Denver, Colorado, United States
2
Local Institution
Rochester, Minnesota, United States
3
Local Institution
Toronto, Ontario, Canada